TAmiRNA brings miRNA tools for children’s bone diseases to ICCBH Salzburg
Press Release | TAmiRNA GmbH
JUNE 18, 2019
Vienna, Austria: Biotech innovators TAmiRNA will be a prominent exhibitor and contributor at the upcoming 9th International Conference on Children’s Bone Health in Salzburg, Austria.
TAmiRNA CEO Dr. Matthias Hackl and his team will present new scientific results on its latest research on application of its osteomiR™ miRNA-based technology using microRNA biomarkers for diagnosis of bone disease in infants and children.
Rapid detection tools
TAmiRNA will be an exhibitor from Booth#3 at the Salzburg Conference Center, where Senior Project Manager Dr. Hanna Dellago and Product Manager Dr. Elisabeth Schraml will present its suite of microRNA-based products and services.
These include the osteomiR™ kit that enables rapid detection of bone specific microRNAs that could serve as novel validated bone biomarkers for bone quality and early diagnosis of skeletal disorders in children.
“We are very pleased to be attending the ICCBH conference, which provides a valuable international forum for the presentation and discussion of current basic and clinical science in the field of bone metabolism and bone mass in children, adolescents and young adults,” said Dr. Hackl.
“We will be able to demonstrate that our novel validated bone biomarkers provide powerful tools for predicting fracture risk in osteoporosis and bone quality, with possibilities of identifying high-risk subsets that qualify for preventive therapeutic treatment and new biomarker targets that give insights into disease mechanism of osteoporosis,” Matthias Hackl added.
Privately owned and headquartered in Vienna, TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.
TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for early diagnosis and prognosis of disease, or as companion diagnostic tests to support treatment decisions.
TAmiRNA’s pipeline includes developments in osteoporosis, cardiovascular disease, type-2 diabetes, and drug safety, which aim to provide ‘microRNA kit’ solutions that enable users to quantify the levels of specific microRNA combinations and platelet function in serum, plasma, urine or other biofluids. The company initially developed kits for bone disease (osteomiR™) and cardiovascular and metabolic diseases (thrombomiRs™).
TAmiRNA also offers contract research services for companies in need of targeted biomarker development. Customers include biopharma companies with drug development programs in human and veterinary medicine, medtech companies and clinical research groups.
More information available at: www.tamirna.com.
About ICCBH 2019
The International Conference on Children’s Bone Health (ICCBH) was founded in 1999 by an international group of independent clinicians and researchers interested in bone metabolism and bone mass in children, adolescents, and young adults. They organised five conferences in their own right up to 2009.
Since 2011, ICCBH conferences have been staged in collaboration with the European Calcified Tissue Society (ECTS). providing an international forum for the presentation and discussion of current basic and clinical science in the field of bone metabolism and bone mass in children, adolescents and young adults.
The 9th International Conference (ICCBH 2019) is a four-day event opening June 22 at the Salzburg Conference Center in Austria and is expected to attract around 450 delegates including clinical researchers, pediatricians, endocrinologists, rheumatologists, nephrologists, hematologists, neurologists, oncologists and orthopedic surgeons.
More information at: https://www.iccbh.org.
Dr. Elisabeth Schraml, Scientific Communications, TAmiRNA GmbH
Tel: +43 (0)660 420 58 56